11 minutes read
Proton beam therapy (PBT) and heavy-ion (carbon-ion) radiotherapy (CIRT) represent the highest level of precision radiation therapy — using the Bragg peak physical phenomenon to deposit radiation dose precisely inside the tumor, maximizing cancer cell destruction while minimizing damage to surrounding normal tissue. China is one of the few countries globally with both proton and heavy-ion capabilities, and the Shanghai Proton and Heavy-Ion Center (SPHIC) is currently the only mature option in China available to international patients. Its 5-year overall survival rate of 69.5% across all cases — and 92.9% for primary nasopharyngeal carcinoma — places its clinical outcomes at the global top tier. Pricing runs approximately 1/3 to 1/4 of US proton therapy. This article walks through SPHIC, China’s other operational proton/heavy-ion centers, the best indications, and the practical access pathway for international patients.
What Are Proton and Heavy-Ion Therapy
Core principle: the Bragg peak
Conventional X-ray (photon) radiation therapy deposits dose along the entire beam path — normal tissue both in front of and behind the tumor receives radiation. Proton and heavy-ion particles have a unique physical property: as they reach a predetermined depth, the dose rises sharply and then drops abruptly (the Bragg peak) — meaning the vast majority of energy is deposited inside the tumor, with very little radiation to normal tissue before or after.
Proton vs Heavy Ion (Carbon Ion) — clinical differences:
| Dimension | Proton Therapy (PBT) | Carbon Ion Therapy (CIRT) |
|---|---|---|
| Particle | Hydrogen nucleus (proton) | Carbon-12 ion |
| Relative biological effectiveness (RBE) | 1.0–1.1 (similar to conventional RT) | 1.5–3.4 (substantially stronger cellular kill) |
| Oxygen enhancement ratio (OER) | Similar to conventional RT | Lower (more effective against hypoxic / radioresistant tumors) |
| Best-suited cancers | Pediatric, skull base, near critical organs | Hypoxic / radioresistant / recurrent tumors |
| Equipment complexity | Moderate | High |
| Global availability | Wider (90+ centers) | More limited (about 15 centers) |
Simple summary: proton is “more precise conventional radiation”; heavy ion combines “dosimetric advantage + biological advantage” — heavy ion offers benefits for certain cancers that proton cannot replicate.
Shanghai Proton and Heavy-Ion Center (SPHIC) — China’s Flagship
SPHIC is China’s first dedicated proton and heavy-ion hospital and the only one currently mature for international patients.
Basic information [1]:
- Public hospital, established by Shanghai Shenkang Hospital Development Center, affiliated with Fudan University
- Opened May 2015
- 150-acre campus, 220 beds
- Equipped with Siemens IONTRIS integrated proton and heavy-ion system — provides both proton and carbon-ion therapy from a single integrated installation
- Treatment planning system: RaySearch RayStation
Cumulative treatment data:
- Approximately 8,900 patients treated cumulatively (2015 through early 2026)
- Annual discharge volume exceeds 1,200
- Has treated 70+ overseas patients including those from the US and UK (publicly reported figures are dated; actual numbers are likely higher)
5-year survival data (published in international peer-reviewed journals) [1]:
| Cancer Type | 5-year Overall Survival (OS) |
|---|---|
| Hospital-wide overall | 69.5% |
| Early-stage lung cancer | 70.3% |
| Primary nasopharyngeal carcinoma | 92.9% |
| Recurrent nasopharyngeal carcinoma (pure carbon ion) | 47% |
| Liver cancer (3-year OS) | 75.4% |
| Locally advanced pancreatic cancer (median OS) | 29.6 months |
Important note on interpreting 5-year overall survival (OS): “5-year OS” reflects the proportion of patients still alive five years after their treatment began. This is not the same as a “cure rate” — the figure includes patients still on treatment, patients with stable disease, patients with controlled recurrence, and patients in long-term remission. 5-year OS is the standard outcome measure in international oncology research and allows direct comparison between centers. A 5-year OS of 92.9% for primary nasopharyngeal carcinoma means that 92.9% of those patients remained alive at the 5-year mark — a result on par with the best centers globally.
SCI publications: SPHIC’s clinical data appears in international peer-reviewed journals including Frontiers in Oncology, Radiotherapy and Oncology, and Cancer Research and Treatment.
International patient services:
- Operates a dedicated International Patient Center
- Provides bilingual services and second-opinion consultations
- Has received 70+ overseas patients (from the US, UK, Singapore, and others)
Other Chinese Proton / Heavy-Ion Centers (Operational in 2026)
Operational:
| Center | Type | Notes |
|---|---|---|
| Shanghai Proton and Heavy-Ion Center (SPHIC) | Proton + Carbon Ion | First choice for international patients |
| Shandong Wanjie Cancer Hospital (Zibo) | Proton | China’s earliest proton center (IBA system) |
| Wuwei Cancer Hospital (Gansu) | Carbon Ion (domestic HIMM) | ~1,820 cases treated |
| Lanzhou Proton and Heavy-Ion Hospital (Gansu) | Proton + Carbon Ion | Public |
| Hefei Ion Medical Center (Chinese Academy of Sciences) | Proton | Operational |
| Shandong Cancer Hospital Proton Center | Proton | Operational |
Under construction or in clinical validation:
| Center | Status | Notes |
|---|---|---|
| Heyou Pinnacle Medical Center (Foshan, Shunde) | Team fully assembled, expected to open to patients by end of 2026 [2] | $278M USD investment; complete proton + heavy-ion configuration; former SPHIC executive vice-president serves as center director |
| Peking Union Medical College Cancer Hospital Shenzhen | Under construction | Part of Fuwai Shenzhen Phase 3 |
| Huazhong University of Science and Technology Union/Tongji Hospital | Under construction | |
| Sichuan Cancer Hospital | Under construction | |
| Xi’an International Medical Center | Under construction | |
| Tianjin Cancer Hospital | Under construction | |
| Shanghai Ruijin Hospital Proton Center | Under construction | |
| Xuzhou Proton and Heavy-Ion Hospital | Under construction | |
| Zhejiang Cancer Hospital | Under construction | |
| CNNC Changsha Cancer Hospital | Under construction |
Practical recommendation for international patients:
- As of mid-2026, SPHIC is the only mature option for international patients in China
- Other public centers (Wuwei, Hefei, etc.) primarily serve domestic patients; international patient service infrastructure is not yet mature
- Once Heyou Pinnacle Foshan opens (expected end of 2026), it will become an important additional option for international patients in southern China
Best Indications: Choosing Between Proton and Heavy Ion
Based on international evidence and SPHIC’s clinical data:
Cancers where heavy ion meaningfully outperforms proton:
- Skull base chordoma / chondrosarcoma — heavy ion is the gold standard
- Bone and soft tissue sarcomas (unresectable or recurrent)
- Adenoid cystic carcinoma (head and neck)
- Mucosal malignant melanoma
- Locally advanced pancreatic cancer
- Recurrent nasopharyngeal carcinoma
- Hepatocellular carcinoma (selected cases)
- Re-irradiation after prior radiation therapy
Cancers suited to proton (heavy ion also possible but proton is sufficient):
- Pediatric cancers (the most important indication — lowest long-term radiation effects)
- Eye melanoma (uveal melanoma)
- Primary nasopharyngeal carcinoma
- Head and neck cancers (many types)
- Prostate cancer
- Early-stage lung cancer
- Esophageal cancer
- Complex CNS tumors (especially pediatric)
Generally not first choice for proton or heavy ion:
- Diffuse cancers (whole-brain radiation, etc.)
- Simple early-stage cancers that can be surgically resected
- Common cancers where conventional radiation is already adequate (most breast cancers, most localized prostate cancers, etc.)
Treatment Process and Timeline
The complete treatment cycle typically spans 5–8 weeks (including evaluation and actual radiation):
Step 1 · Evaluation and enrollment (1–2 weeks)
- Pathology confirmation + staging
- Imaging (contrast CT, MRI, PET-CT)
- Cardiopulmonary, hepatic, renal function assessment
- MDT consultation to confirm suitability for proton/heavy ion
- Treatment plan determination
Step 2 · Treatment planning (1 week)
- Simulation CT (in radiation treatment position)
- Treatment plan design (physician + medical physicist + dosimetrist)
- Treatment plan verification
Step 3 · Actual radiation therapy (3–6 weeks)
- Typically once daily, 5 days per week
- Each session takes 15–30 minutes (equipment setup + actual irradiation)
- Total course 15–30 fractions (depending on cancer type and protocol)
Step 4 · Post-treatment follow-up
- 4–6 weeks post-treatment evaluation (assess early response)
- Then ongoing long-term follow-up (assess outcomes and late effects)
Typical SPHIC treatment time:
- Total time in China approximately 6–10 weeks (including pre-treatment evaluation, treatment, and initial follow-up)
- Most patients do not require hospitalization during treatment (come to the hospital daily and return to a hotel)
International Pricing Comparison
| Country / Center | Standard Course Total Cost (USD) |
|---|---|
| US proton therapy | $100,000 – $200,000 (typical $125K – $150K) |
| Germany HIT Heidelberg (carbon ion) | Including hospitalization approximately $85,000 – $110,000 |
| Switzerland PSI (proton) | Swiss insurance covers; private rates are 2× standard photon RT |
| Japan (with national insurance) | Proton ¥1.6M – ¥2.735M (~$14K – $21K) |
| Japan (international self-pay) | $30,000 – $50,000 |
| Korea (Samsung SMC and others) | $22,000 – $45,000 (average ~$33,500) |
| China SPHIC | ~$43,000 (treatment) / ~$48,000 (all-inclusive with hospitalization) |
Core comparison:
- China SPHIC costs approximately 1/3 to 1/4 of US proton therapy
- Comparable pricing to Japan international self-pay and Korea
- Approximately 40–55% less than Germany HIT carbon ion
Practical implications for international patients:
- Patients from the US, UK, Europe: China proton/heavy ion is a meaningfully economical option
- Patients from Japan, Korea: SPHIC’s pricing advantage over home country is modest, but heavy-ion capability + comprehensive clinical data is an independent reason to choose
- Patients from Southeast Asia, Middle East: China SPHIC offers the strongest combination of geographic convenience + pricing + clinical capability
SPHIC International Patient Access Pathway
Best-suited patients:
- Confirmed indications above (especially skull base tumors, recurrent NPC, pediatric cancers, locally advanced pancreatic cancer)
- Home country proton therapy is inaccessible or unaffordable
- Disease fits the clinical benefit profile of proton/heavy ion (not all cancers benefit)
Typical 6–10 week timeline:
| Phase | Duration | Notes |
|---|---|---|
| Pre-travel evaluation and document preparation | 4–6 weeks (remote) | Pathology + imaging + prior treatment |
| Arrival at SPHIC + on-site evaluation | 1 week | MDT consultation confirms plan |
| Treatment planning + verification | 1 week | Simulation + plan design |
| Actual radiation therapy | 3–6 weeks | Daily, 5×/week |
| Initial post-treatment follow-up | 1–2 weeks | Early response assessment |
| Return home + long-term remote follow-up | ≥2 years | Coordinated with home physician |
Practical notes:
- S2 medical visa (≤180 days) is sufficient for the complete treatment cycle
- Most patients do not require hospitalization; can stay in a hotel near the hospital
- Prepayment: typically 50% of treatment fees required upfront
- Insurance: some international medical insurance plans (MSH International, Cigna Global, etc.) cover proton therapy — confirm your specific policy before traveling
Side Effects and Risks
Proton and heavy-ion side effects are typically milder than conventional radiation, but still exist:
Early side effects (during treatment and the weeks following):
- Local skin reaction (redness, itching, mild peeling)
- Fatigue in the treatment area
- Local inflammatory reaction (oral mucositis for head/neck radiation, cough for lung radiation)
- Most resolve within 4–8 weeks
Late side effects (months to years post-treatment):
- Local tissue fibrosis
- Secondary malignancy (very low probability, but long-term monitoring required)
- Site-specific functional effects (head/neck radiation can affect swallowing; pelvic radiation can affect fertility)
Important safety advantage: late side effects with proton and heavy-ion therapy are significantly lower than with conventional radiation — this is a core reason international patients choose proton and heavy-ion therapy.
Common Questions
Proton vs heavy ion — which is better? Depends on the cancer. Heavy ion is meaningfully superior for hypoxic, radioresistant, and recurrent situations; proton is sufficient for pediatric, near-critical-organ, and dose-precision situations. SPHIC’s advantage is having both capabilities — the physician selects the optimal approach for your specific case.
Can I have both proton and heavy ion at SPHIC? Yes. SPHIC uses “proton + heavy-ion sequential protocols” for some patients — for example, starting with proton and continuing with heavy ion, or the reverse, to maximize outcomes.
Who does SPHIC accept as international patients? Any international patient who meets the proton or heavy-ion indication criteria. SPHIC does not restrict by nationality or insurance type. Whether your specific case is suitable requires MDT evaluation of your records and imaging.
How is SPHIC’s English service? SPHIC operates a dedicated International Patient Center providing English and other multilingual services. Some clinical physicians have overseas training and can communicate directly in English. Routine nursing and technical staff communicate through interpreters.
Is SPHIC’s treatment quality internationally recognized? Yes. SPHIC’s clinical data is continuously published in international peer-reviewed journals; treatment standards follow international guidelines (NCCN, ESMO, etc.); the treatment equipment (Siemens IONTRIS) is the same model used at top global centers including Germany HIT and Austria MedAustron.
When will Heyou Pinnacle Foshan’s proton and heavy-ion center open? As of mid-2026, the Heyou Pinnacle proton and heavy-ion center is still in clinical validation. It is expected to open to patients by end of 2026. Until Heyou opens, international patients seeking proton or heavy-ion therapy should choose SPHIC.
Can I receive part of my treatment at home and then continue in China? Generally not recommended — proton and heavy-ion therapy is a complete treatment plan, and splitting between centers affects dose integration and outcome assessment. Complete the full course at SPHIC.
Is SPHIC safe for pediatric patients? SPHIC has dedicated pediatric oncology proton therapy experience — pediatric cancers are one of the most important indications for proton therapy (avoiding long-term radiation-induced developmental issues and secondary tumors). SPHIC has treated multiple pediatric oncology cases.
Bottom Line
SPHIC is the first choice for international patients seeking proton and heavy-ion therapy in China:
- World-class clinical data (hospital-wide 5-year OS 69.5%; primary nasopharyngeal carcinoma 5-year OS 92.9%)
- Simultaneous proton + heavy-ion capability — physicians can select the optimal approach for the case
- Pricing approximately 1/3 to 1/4 of US (~$43K–$48K USD vs US $125K–$150K)
- Full international patient services — bilingual, IMD channel, 70+ cumulative overseas patient experience
Best-suited international patients for SPHIC:
- Skull base tumors, chordomas, chondrosarcomas
- Recurrent or primary nasopharyngeal carcinoma
- Locally advanced pancreatic cancer
- Hepatocellular carcinoma (selected cases)
- Pediatric cancers
- Uveal melanoma
- Re-irradiation after prior radiation therapy
Total time in China: 6–10 weeks (including evaluation, treatment, and initial follow-up)
If your cancer may be suitable for proton or heavy-ion therapy, MedCareInChina can establish communication with SPHIC’s International Patient Center — based on your records and imaging, SPHIC specialists will provide an indication assessment, with clear judgment on “whether suitable, recommended plan, expected timeline, and estimated cost.”
→ Send your case to hello@medcareinchina.com
See Service & Refund Policy and Medical Disclaimer for service boundaries.
Sources
- Shanghai Proton and Heavy-Ion Center (SPHIC) — Equipment: Siemens IONTRIS integrated proton and heavy-ion system. Opened 2015, cumulative ~8,900 cases treated. Hospital-wide 5-year OS 69.5%; primary nasopharyngeal carcinoma 5-year OS 92.9%; liver cancer 3-year OS 75.4%. Standard course 278,000 RMB, all-inclusive ~310,000 RMB. Sources: SPHIC official site https://www.sphic.org.cn/ ; Shanghai Municipal Government English profile https://english.shanghai.gov.cn/en-Hospitals/20241012/5bcd1afd5752428da050337895efafeb.html ; Global Times https://www.globaltimes.cn/page/202304/1289019.shtml ; MedBridge https://www.medbridgenz.com/sphic-hospital ; Clinical data: Frontiers in Oncology https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.819905/full
- Heyou Pinnacle Medical Center Proton and Heavy-Ion Center — Investment exceeding $278M USD, complete proton + heavy-ion configuration. As of mid-2026, still in clinical validation; expected to open to patients by end of 2026. Former SPHIC executive vice-president serves as center director. Source: Heyou Pinnacle IMC https://imc.hyhospital.com/
- Wuwei Heavy-Ion Treatment Center (Gansu) — Domestic HIMM carbon ion system, in clinical operation since March 2020, ~1,820 cases treated. Source: PTCOG https://www.ptcog.online/summary-of-the-construction-and-operation-of-heavy-ion-radiotherapy-systems-in-china/
- China proton and heavy-ion center 2026 list — 14 operational centers (combined proton + heavy ion). Source: MedBridge https://www.medbridgenz.com/post/heavy-ion-therapy-china-guide
- US proton therapy pricing — Typical course $100,000 – $200,000 (average $125K – $150K). Sources: AMedical https://www.amedical.az/en/blogs/news/proton-therapy-cost ; Bookimed https://us-uk.bookimed.com/article/proton-beam-therapy-cost-ultimate-insights
- Germany HIT Heidelberg heavy-ion pricing — All-inclusive with hospitalization approximately $85,000 – $110,000. Source: Heidelberg University Hospital https://www.heidelberg-university-hospital.com/
- Japan proton and heavy-ion pricing — Under national insurance ¥1.6M – ¥2.735M; international patient self-pay $30K – $50K.
- Korea proton therapy pricing — $22,000 – $45,000 (average $33,500). Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0308961
- Proton vs heavy-ion clinical differences — Heavy ion RBE 1.5–3.4; proton RBE 1.0–1.1. Heavy ion meaningfully superior for: skull base chordoma, chondrosarcoma, bone/soft tissue sarcoma, adenoid cystic carcinoma, mucosal melanoma, locally advanced pancreatic cancer, recurrent nasopharyngeal carcinoma, and other “photon-resistant tumors.” Sources: Frontiers in Oncology https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00082/full ; NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605728/
